Recurrent vulvovaginal candidiasis affects 3-6% of women who are of childbearing age. Usually, sufferers have at least four acute attacks per year. It is difficult to control and is never completely cured until menopause. "The women who suffer from VVC are prone to it mostly because of their genetics, and it can have a significant effect on their quality of life, affecting not just their physical condition but their psychological state," says Dr. William Ledger, Professor Emeritus of Obstetrics and Gynecology at Weill Cornell Medical College, New York. Moreover, thrush is still considered somewhat of a taboo, and the sufferers feel that others consider it an unimportant minor problem.

In contrast to readily available pharmacy treatments, which merely treat the symptoms, the PEV7 vaccine targets and treats the root cause of Candidiasis.

"Over-the-counter treatments work on the short term problem but there's nothing to stop it coming back. If the vaccine works it will be a miracle to the women who suffer," continues Dr. Ledger.

Phase I will comprise 48 women of childbearing age who have not previously suffered from thrush. The women will receive three doses of the vaccine, either through an injection into the arm once a month for three months, or through a pessary inserted into the vagina three times a month for three months.

SOURCE Pevion Biotech